首頁 › 非小細胞肺癌 › 田納西州 › Knoxville
Knoxville, TN 的 非小細胞肺癌 臨床試驗
14 項針對 非小細胞肺癌 的研究正在 Knoxville（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
招募中2/3 期
- Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891, Knoxville
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- Thompson Cancer Survival Center ( Site 0168), Knoxville
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
招募中3 期
- The University of Tennessee Medical Center ( Site 3223), Knoxville
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Tennessee Cancer Specialists, Knoxville
- Tennessee Cancer Specialists - Parkwest Location, Knoxville
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- University of Tennessee Medical Center Knoxville ( Site 0082), Knoxville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Tennessee Cancer Specialists Dowell Springs location, Knoxville
- University of Tennessee Medical Center, Knoxville
- Tennessee Cancer Specialists - Parkwest Location, Knoxville
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Tennessee Cancer Specialists, Knoxville
- University of Tennessee, Knoxville
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- University of Tennessee Medical Center, Knoxville
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
招募中2 期
- University of Tennessee Medical Center, Knoxville
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- University of Tennessee Medical Center, Knoxville
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
招募中1/2 期
- University of Tennessee Medical Center, Knoxville
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- University of Tennessee Medical Center, Knoxville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- University of Tennessee Medical Center, Knoxville
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- University of Tennessee Medical Center, Knoxville
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Knoxville 的其他研究
- 肥胖症10 項研究
- 肺癌10 項研究
- 乳癌9 項研究
- 癌症（所有類型）8 項研究
- 過重7 項研究
- 心臟衰竭7 項研究
- 轉移性癌症7 項研究
- 心血管疾病6 項研究
- 黑色素瘤5 項研究
- 第二型糖尿病5 項研究
- 高血壓5 項研究
- 慢性阻塞性肺病5 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。